Afshari discussed tests including SepsiTest (Molzym, Bremen, Germany), which detects more than 300 pathogens and markers of drug resistance and has a turnaround time of 8-12 h; VYOO LOOXSTER (SIRS-Lab, Jena, Germany), which detects more than 40 pathogens within 8 h; PLEX-ID (Abbott Molecular, Carlsbad, CA, USA), which detects several pathogens (including viruses) and has a turnaround of 8-12 h; and Magiplex (Seegene, Seoul, South Korea), the most recent multiplex device, which detects more than 90 diff erent pathogens and has a turnaround time of 3-4 h.
SeptiFast (Roche, Manheim,Germany) is the most used assay; it has a turnaround time of 6 h, can detect meticillin-resistant Staphylococcus aureus, and costs €150-200 per test. Ashari discussed a study from Peter Michael Rath and colleagues of patients with sepsis in intensive-care units after liver transplantation. The rate of SeptiFast positivity was significantly higher in patients who had undergone liver transplantation (52·3%) than in those who had not (30·5%; p=0·0009).
Afshari also reported on use of MALDI-TOF MS (Bruker Daltonics, Bremen, Germany) to identify organisms that are difficult to detect by conventional methodseg, mycobacteria, non-fermenting bacteria. The instrument has three components: a specimen-ionisation chamber, a time-of-flight mass analyser, and a particle detector. Sample preparation is simple and involves transferring a portion of an isolated colony onto a target plate. The US Food and Drug Administration has not yet approved any commercial MALDI-TOF MS system for clinical use. However, this technology offers improved turnaround time and could eventually supplant conventional microbiological identifi cation methods.
MERS-CoV
In a special plenary session, Ziad A Memish (Deputy Minister for Public Health, Saudi Arabia) gave an up-to-date presentation about Middle East respiratory syndrome coronavirus (MERS-CoV) in the Middle East and beyond. A new virus, human coronavirus-Erasmus Medical Center, was identified in 2012 from the sputum of a 60-yearold patient in Saudi Arabia, who died of a severe acute respiratory crisis. 3 months later, WHO was informed of a Qatari national transferred to UK for treatment, in whom the same type of virus was implicated.
In November, 2012, the new coronavirus was renamed Middle East coronavirus and was identified retrospectivley in samples from April, 2012, which were obtained from 14 patients with severe pneumonia in Zarqa, Jordan. At the time of the conference, 77 laboratory-confirmed cases of MERS-CoV have been reported to WHO (40 fatal). As of July 10, 81 cases have been laboratory confi rmed. All cases have been linked to one or more of Jordan, Qatar, Saudi Arabia, United Arab Emirates, or the UK. 62 cases (34 fatal) have been reported by Saudi Arabia. Mild asymptomatic disease seems to be common, which makes case defi nition diffi cult.
Memish also reported about a hospital outbreak of 23 cases in Al-Hasa, Saudi Arabia. Of 217 household contacts investigated, five family members and two health workers developed MERS-CoV. Interventions included monitoring of hand hygiene, provision of masks to all patients, exclusion of visitors, and testing for MERS-CoV. Discussion about treatment is ongoing in Saudi Arabia. Steroids, ribavirin, and interferon were tried in a few places without clear benefi ts. The animal reservoir also remains unclear. 1100 samples from diff erent species of bats in three diff erent locations in Saudi Arabia were analysed, but MERS-CoV was not detected. So far, there is no clear epidemiological link to exposure to a specifi c animal species.
Vaccination against resistance
The keynote lecture was given by Keith Klugman (Emory University, Atlanta, GA, USA) and was about how vaccines can reduce antibiotic resistance. He reported that pneumococcal conjugate vaccine has reduced the burden of antibiotic-resistant pneumococci, particularly as causes of invasive infections, in the USA. In many countries, serotype 19A has emerged as a major cause of invasive pneumococcal disease, and both antibiotic selection and vaccination can select for these highly resistant clones. Resistance is also emerging in types 6C, 15A, 23A, and 35B. 
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